<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000963</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 144</org_study_id>
    <secondary_id>11119</secondary_id>
    <nct_id>NCT00000963</nct_id>
  </id_info>
  <brief_title>A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine</brief_title>
  <official_title>A Randomized Comparative Trial of Two Doses of 2',3'-Dideoxyinosine (ddI) in Children With Symptomatic HIV Infection Who Are Either Unresponsive to Zidovudine and/or Who Are Intolerant to Zidovudine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness, safety, and tolerance of two doses of didanosine (ddI) in the&#xD;
      treatment of children with symptomatic HIV disease who have had to discontinue zidovudine&#xD;
      (AZT) because of intolerance and/or who have experienced progressive disease while on AZT.&#xD;
&#xD;
      The progression of immunodeficiency due to HIV infection can be delayed by using AZT. The&#xD;
      benefits of AZT in adults with AIDS and severe AIDS-related complex (ARC) appear to last for&#xD;
      approximately 12 to 18 months, at which time most patients have progressive deterioration.&#xD;
      Recently published literature has described a reduced sensitivity of HIV isolated from&#xD;
      patients after prolonged AZT treatment. Although the clinical significance of this is&#xD;
      unclear, it makes the development of new antiretroviral drugs important.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The progression of immunodeficiency due to HIV infection can be delayed by using AZT. The&#xD;
      benefits of AZT in adults with AIDS and severe AIDS-related complex (ARC) appear to last for&#xD;
      approximately 12 to 18 months, at which time most patients have progressive deterioration.&#xD;
      Recently published literature has described a reduced sensitivity of HIV isolated from&#xD;
      patients after prolonged AZT treatment. Although the clinical significance of this is&#xD;
      unclear, it makes the development of new antiretroviral drugs important.&#xD;
&#xD;
      Children who show AZT intolerance and/or progressive disease after 6 months of AZT therapy&#xD;
      receive oral ddI at 1 of 2 doses for a minimum of 48 weeks, with a 48-week extension.&#xD;
      Patients are seen for clinical and laboratory evaluations at scheduled times during the&#xD;
      study. (Per 5/12/92 amendment, new patients will not be enrolled in the pharmacokinetics&#xD;
      studies.) Per 10/31/94 amendment: Patients are eligible to receive blinded study drug for an&#xD;
      additional 8-16 weeks after the final on-study visit, but no later than 2/15/95.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">September 1995</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>300</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prophylaxis treatment for Pneumocystis carinii pneumonia (PCP).&#xD;
&#xD;
          -  Immunoglobulin.&#xD;
&#xD;
          -  Maintenance therapy with amphotericin B (l mg/kg) up to 5 days/week.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Blood transfusions.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prophylaxis treatment for Pneumocystis carinii pneumonia (PCP).&#xD;
&#xD;
        Patients enrolled in ACTG 128 and ACTG 138 must meet study end points or meet protocol&#xD;
        definitions for being permanently off zidovudine (AZT) before enrolling in this study.&#xD;
&#xD;
          -  Patients currently enrolled in ACTG 051 who have not reached the study end points but&#xD;
             who meet the entry criteria for ACTG 144 may be co-enrolled in ACTG 144.&#xD;
&#xD;
          -  Patient or guardian available to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded.&#xD;
&#xD;
          -  Hypersensitivity to didanosine (ddI).&#xD;
&#xD;
          -  Symptomatic cardiomyopathy.&#xD;
&#xD;
          -  Seizures that are not well controlled by ongoing anticonvulsant therapy.&#xD;
&#xD;
          -  Symptomatic pancreatitis.&#xD;
&#xD;
          -  Grade 1 or higher peripheral neuropathy.&#xD;
&#xD;
          -  Active malignancy requiring chemotherapy.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Zidovudine (AZT), other antiretroviral agents, biological modifiers, and&#xD;
             investigational medications.&#xD;
&#xD;
        Avoid:&#xD;
&#xD;
          -  Drugs with potential to cause peripheral neuropathy or pancreatitis.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Active malignancy requiring concomitant chemotherapy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretroviral agents other than zidovudine (AZT) or dideoxycytidine (ddC) within 4&#xD;
             weeks of study entry.&#xD;
&#xD;
          -  Immunomodulating agents such as interferons, isoprinosine, or interleukin-2 within 2&#xD;
             weeks of entry.&#xD;
&#xD;
          -  Any other experimental therapy within 1 week of entry.&#xD;
&#xD;
          -  Drugs that have or will cause prolonged neutropenia, significant pancreatitis,&#xD;
             significant nephrotoxicity, or peripheral neuropathy within 1 week of entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frenkel LM</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Bryson Y</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Stiehm R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Long Beach Memorial Med. Ctr., Miller Children's Hosp.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Usc La Nichd Crs</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hosp. &amp; Research Ctr. Oakland, Ped. Clinical Research Ctr. &amp; Research Lab.</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Maternal, Child, and Adolescent HIV CRS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Pediatric AIDS CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Connecticut Health Ctr., Dept. of Ped.</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Med. Ctr., ACTU</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Univ. Washington DC NICHD CRS</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Miami Ped. Perinatal HIV/AIDS CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Univ. School of Medicine, Dept. of Peds., Div. of Infectious Diseases</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook County Hosp.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Illinois College of Medicine at Chicago, Dept. of Peds.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Children's CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane/LSU Maternal/Child CRS</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Maryland Med. Ctr., Div. of Ped. Immunology &amp; Rheumatology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp. &amp; Health System - Dept. of Peds., Div. of Infectious Diseases</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HMS - Children's Hosp. Boston, Div. of Infectious Diseases</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BMC, Div. of Ped Infectious Diseases</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Health, Baystate Med. Ctr.</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WNE Maternal Pediatric Adolescent AIDS CRS</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan NICHD CRS</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ - Robert Wood Johnson</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hosp. &amp; Med. Ctr. of New Jersey</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Albany Medical Center, Dept. of Peds.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx-Lebanon Hosp. IMPAACT CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore-Long Island Jewish Health System, Dept. of Peds.</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Hosp., Div. of Infectious Diseases</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Med. Ctr., Dept. of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hosp. NICHD CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia IMPAACT CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Incarnation Children's Ctr.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem Hosp. Ctr. NY NICHD CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester ACTG CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Stony Brook NICHD CRS</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Med. Univ., Dept. of Peds.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DUMC Ped. CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hosp. of Philadelphia IMPAACT CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hosp. for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Univ. of South Carolina, Div. of Ped. Infectious Diseases</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Med. Ctr. Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hosp. CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UW School of Medicine - CHRMC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Hosp. Ram√≥n Ruiz Arnau, Dept. of Peds.</name>
      <address>
        <city>Bayamon</city>
        <zip>00956</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hosp. PR NICHD CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Carey VJ, Yong F, Frenkel L, McKinney R. Enhancing the prognostic value of bodily growth histories in HIV-positive pediatric cohorts. Int Conf AIDS. 1996 Jul 7-12;11(2):134 (abstract no WeC3444)</citation>
  </reference>
  <reference>
    <citation>Perrier M, Schwarz T, Gonzalez O, Brounts S. Squamous cell carcinoma invading the right temporomandibular joint in a Belgian mare. Can Vet J. 2010 Aug;51(8):885-7.</citation>
    <PMID>21037891</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Didanosine</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Didanosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

